Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.
Dirk Schadendorf, MD, Essen University Hospital
Advertisement
Articles by Dirk Schadendorf, MD, Essen University Hospital
Advertisement
Latest Updated Articles
Ipilimumab Dosing Significance in Adjuvant SettingPublished: October 12th 2020 | Updated:
Immune Checkpoint Inhibition in Stage IV MelanomaPublished: October 12th 2020 | Updated:
Triple Therapy for the Management of MelanomaPublished: October 12th 2020 | Updated:
COMBI-AD Trial 5-Year Analysis DataPublished: October 12th 2020 | Updated:
COMBI-i Trial Data UpdatesPublished: October 12th 2020 | Updated:
Checkpoint Blockade Trial Data UpdatesPublished: October 12th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5